Preclinical antitumor activity of XK469 (NSC 656889)

Investigational New Drugs

Volumn 16, Issue 4, 1998, Pages 287-296

  LoRusso, Patricia M ^a,c   Parchment, Ralph ^a   Demchik, Lisa ^a   Knight, Juianna ^a   Polin, Lisa ^a   Dzubow, Janet ^b   Behrens, Carl ^b   Harrison, Barbara ^b   Trainor, George ^b   Corbett, Thomas H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUPONT COMPANY   (United States)

^c HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Assure ; Human xenograft and mouse activity; Myelotoxicity; NSC 697887*; NSC 698215*; NSC 698216*; Preclinical development; Quinoxaline; XB947; XK469

Indexed keywords

ANTINEOPLASTIC AGENT; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG; XK 469;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; COLON ADENOCARCINOMA; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TOLERANCE; EXPERIMENTAL NEOPLASM; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS CARCINOMA; PRIORITY JOURNAL; SCID MOUSE; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MICE, SCID; QUINOXALINES; TUMOR CELLS, CULTURED;

EID: 6544243328     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. LoRusso PM, Demchik L, Knight J, Polin L, Behrens CH, McRipley R, Gross JL, Harrison BA, Corbett TH: Preclinical antitumor activity of XK469. Proc AACR 35: 2390, 1994.
2. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785; Davis et al., 0,323,727 A2.
3. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785; Davis et al., 0,323,727 A2.
4. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785; Davis et al., 0,323,727 A2.
5. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785; Davis et al., 0,323,727 A2.
6. Fawzi, US Patent 4,609,396; Ura et al., US Patent 4,629,493; Serban et al., US Patent 4,803,273; Serban et al., US Patent 4,655,819; Serban et al., EP 0,023,785; Davis et al., 0,323,727 A2.
7. Corbett TH, Valeriote RA, Polin L, et al. Discovery of solid tumor active agents using a soft-agar-colony-formation-disk-diffusion-assay. In: Valeriote FA, Corbett TH, Baker LH (eds), Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, Norwell, Massachusetts, Kluwer Academic Publishers, 1992, pp. 35-87.
8. LoRusso PM, Polin L, Biernat LA, Valeriote FA, Corbett TH: Activity of datelliptium acetate (NSC311152; SR95156A) against solid tumors of mice. Invest New Drugs 8:253-261, 1990.
9. Corbett TH, Valeriote FA. Rodent models in experimental chemotherapy. In: Kallman RF (ed), The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations, Elmsford, NY, Pergamon Press, 1987, pp 233-247.
10. Corbett TH, Griswold DP Jr., Roberts BJ, Peckham JC, Schabel FM Jr: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434-2439, 1975.
11. Corbett RH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP Jr., Schabel FM Jr. Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res. 42: 1701-1715, 1982.
12. Corbett TH, Griswold DP Jr., Roberts BJ, Peckham JC, Schabel FM Jr. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 2660-2680, 1977.
13. Corbett TH, Roberts BJ, Trader MW Jr., Laster WR Jr., Griswold DP Jr., Schabel FM Jr. Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66(5): 1187-1200, 1982.
14. 57B1/6 mice. Cancer Res 44: 717-726, 1984.
15. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel Jr. FM. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep, 62: 1471-1488, 1978.
16. Parchment RE, Huang M., Erickson-Miller CL: Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol 21: 241-250, 1993.
17. Parchment RE, Volpe DA, LoRusso PM, Erickson-Miller CL, Huang M, Murphy MJ. Jr., Grieshaber CK: An in vivo-in vitro correlation of the myelotoxicity of 9-methoxypyrazoloacridine (PZA, NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow. J Natl Cancer Institute 86: 273-280, 1994.
18. Erickson-Miller CL, May R, Tomaszewski J, Osborn B, Murphy MJ. Jr., Page JG, Parchment RE: Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chem Pharmacol 39: 467-472, 1997.
19. Parchment RE: Alternative testing systems for evaluating non-carcinogenic, hematologic toxicity. Environmental Health Perspectives 106[Suppl. 2]:541-558, 1998.
20. Parchment RE, Murphy MJ Jr: Human hematopoietic stem cells: Laboratory assessment and response to toxic injury. In: Sipes G, McQueen CA, Gandolfi AJ (eds), Comprehensive Toxicology, Pergamon, New York, NY, Volume 4, 1997, pp 335-361.
21. Parchment RE, Gordon M, Grieshaber CK, Sessa C, Volpe D, Ghielmini M: Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol 9: 357-364, 1998.
22. Corbett TH, LoRusso P, Demchick L, Simpson C, Pugh S, White K, Kushner J, Polin L, Meyer J, Czarnecki J, Heilbrun L, Horwitz JP, Gross JL, Behrens CH, Harrison BA, McRipley RJ, Trainor G: Preclinical antitumor efficacy of analogs of XK469: Sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)pheno xy]propionate. Investig New Drugs, 16: 129-139, 1998.
23. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey and man. Cancer Chemother Rep 50: 219-244, 1966.